Kyle Richards’s daughter, Sophia Umansky, shared alarming footage of her hair loss after rapidly losing weight with the help ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Zepbound, Mounjaro, and Ozempic can be used for weight loss. But the Food and Drug Administration (FDA) has only approved Zepbound for weight loss. Mounjaro and Ozempic are FDA approved to help ...

Kyle Richards and Mauricio Umansky's daughter, Sophia Umansky, posted a TikTok and revealed that she’s been taking Mounjaro for around four months. She explained that she believes the weight-loss drug ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

U.S. multinational activity propelled the Irish economy to 3.2% growth in the first quarter, as Trump fears come into focus.

As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.